#1 Clinical Trials Search in Europe

Cytisine

Cytisine, a plant-based compound, has emerged as a potential alternative to existing smoking cessation medications. This article explores recent clinical trials investigating cytisine’s effectiveness, safety, and optimal dosing for helping smokers quit. We’ll examine how cytisine compares to other treatments and its potential benefits for different groups of smokers.

Table of Contents

What is Cytisine?

Cytisine is a medication used to help people quit smoking. It’s a plant-based substance that has been used for smoking cessation in some parts of Eastern and Central Europe for over 50 years[1]. Cytisine is also known by other names, including:

  • Tabex
  • Desmoxan
  • Cytisinicline

While it has been used in Europe for a long time, cytisine is not yet approved for use in many countries such as New Zealand, Australia, the UK, or the US[1].

How Cytisine Works

Cytisine works in a similar way to other smoking cessation medications like varenicline (Champix). It acts on the brain by:

  • Stimulating nicotine receptors, but to a lesser extent than nicotine itself
  • Blocking nicotine from binding to its receptors
  • Reducing the rewarding effects of smoking cigarettes

This mechanism helps reduce cravings and withdrawal symptoms when a person stops smoking[1].

Conditions Treated

Cytisine is primarily used for:

  • Smoking Cessation: Helping people quit smoking tobacco cigarettes[1]
  • Vaping Cessation: Some studies are also looking at its effectiveness in helping people quit e-cigarettes or vaping[2]

Dosage and Administration

Cytisine is typically taken as oral tablets. The dosage schedule can vary, but one common regimen is[3]:

  • Days 1-3: 1 tablet every 2 hours (maximum 6 per day)
  • Days 4-12: 1 tablet every 2.5 hours (maximum 5 per day)
  • Days 13-16: 1 tablet every 3 hours (maximum 4 per day)
  • Days 17-20: 1 tablet every 5 hours (maximum 3 per day)
  • Days 21-25: 1-2 tablets per day

This schedule is designed to gradually reduce the dose over 25 days. It’s important to follow the prescribed dosage carefully and not exceed the recommended amount.

Effectiveness

Studies have shown that cytisine can be effective for smoking cessation:

  • It has been found to be more effective than placebo (a dummy pill) in helping people quit smoking
  • Some research suggests it may be more effective than nicotine replacement therapy (NRT)[1]
  • Ongoing studies are comparing its effectiveness to other smoking cessation medications like varenicline[4]

Side Effects and Safety

Like all medications, cytisine can cause side effects. Researchers are conducting studies to better understand its safety profile. Some potential side effects and safety considerations include:

  • Nausea
  • Vomiting
  • Stomach discomfort
  • Changes in heart rate or blood pressure
  • Headache
  • Sleep disturbances

It’s important to discuss potential side effects with a healthcare provider before starting cytisine. They can help weigh the benefits against the risks for each individual[2].

Ongoing Research

Several clinical trials are currently underway to further investigate cytisine. These studies aim to:

  • Evaluate the long-term safety of cytisine when used for up to 52 weeks[2]
  • Compare the effectiveness of cytisine to other smoking cessation medications like varenicline[4]
  • Investigate the use of cytisine in combination with exercise programs for smoking cessation[3]
  • Study the effectiveness of cytisine in people who also have alcohol use disorder[5]
  • Examine how food affects the absorption and effectiveness of cytisine[6]

These ongoing studies will help researchers better understand how cytisine works, its optimal dosing, and its effectiveness compared to other treatments for smoking cessation.

Aspect Details
Mechanism of Action Partial agonist of nicotine receptors; reduces cravings and withdrawal symptoms
Dosing Typically oral tablets, tapered over 25 days (e.g., 1.5 mg every 2 hours initially, reducing over time)
Efficacy Shown to be more effective than placebo; potentially comparable to varenicline
Safety Profile Generally well-tolerated; common side effects include nausea and sleep disturbances
Cost Significantly less expensive than varenicline
Availability Used in Eastern Europe for decades; not yet approved in many Western countries
Ongoing Research Studies on optimal dosing, long-term safety, and effectiveness in specific populations (e.g., those with alcohol use disorder)

FAQ

  • What is cytisine and how does it work for smoking cessation? Cytisine is a plant alkaloid that acts similarly to nicotine in the brain. It partially stimulates nicotine receptors, which can help reduce cravings and withdrawal symptoms when quitting smoking. At the same time, it blocks nicotine from fully binding to these receptors, potentially reducing the rewarding effects of smoking.
  • How is cytisine typically administered in clinical trials? In most trials, cytisine is given as oral tablets following a gradual dosing schedule over 25 days. The dosage usually starts higher and tapers down over time. For example, one common schedule begins with 1.5 mg taken every 2 hours (6 times daily) for the first few days, then gradually reduces frequency and dosage over the following weeks.
  • How does cytisine compare to other smoking cessation medications? Some studies have compared cytisine to varenicline (Champix), another smoking cessation medication. While both work similarly, cytisine is significantly less expensive. Early results suggest cytisine may be at least as effective as varenicline in helping smokers quit, but more research is needed for definitive comparisons.
  • What are the potential side effects of cytisine? Common side effects reported in clinical trials include nausea, vomiting, and sleep disturbances. However, most trials found cytisine to be well-tolerated overall. Researchers are continuing to study the safety profile of cytisine, especially with longer-term use and higher doses.
  • Is cytisine available everywhere for smoking cessation? Cytisine has been used for smoking cessation in parts of Eastern and Central Europe for over 50 years. However, it is not yet approved for use in many countries, including the United States, United Kingdom, and Australia. Clinical trials are ongoing to gather more data on its effectiveness and safety to support potential approval in other regions.

Ongoing Clinical Trials on Cytisine

Unfortunately, we did not find any clinical trials matching the selected criteria. Try changing the filter settings or broadening the search criteria to see more available research participation opportunities.

Glossary

  • Cytisine: A plant-based compound that acts on nicotine receptors in the brain to help reduce cravings and withdrawal symptoms when quitting smoking.
  • Varenicline: A prescription medication (brand name Champix) used for smoking cessation that works similarly to cytisine but is more expensive.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a real drug against no treatment.
  • Adverse Event: Any undesirable experience associated with the use of a medical product in a patient. This can range from mild side effects to serious health issues.
  • Point-prevalence abstinence: A measure of smoking cessation success where a person reports not smoking at all during a specific time period (often 7 days) prior to assessment.
  • Continuous Abstinence: Complete abstinence from smoking from a set quit date until a follow-up point, with no lapses allowed.
  • Nicotine Withdrawal: The physical and psychological symptoms that occur when a person stops using nicotine after regular use, such as irritability, anxiety, and cravings.
  • Fagerstrom Test for Nicotine Dependence (FTND): A standard tool used to assess the intensity of physical addiction to nicotine.

References

  1. https://clinicaltrials.gov/study/NCT02585024
  2. https://clinicaltrials.gov/study/NCT06435221
  3. https://clinicaltrials.gov/study/NCT06579846
  4. https://clinicaltrials.gov/study/NCT04015414
  5. https://clinicaltrials.gov/study/NCT05729243
  6. https://clinicaltrials.gov/study/NCT03268343